Relay Therapeutics Prices $296.8M Public Offering at $12.00/Share

summarizeSummary

Relay Therapeutics secured $296.8 million in net proceeds from a public offering of 26,354,167 shares of common stock priced at $12.00 per share, including the full exercise of the underwriters' option.

check_boxKey Events · Financing and Capital Events · RLAY

• Public Offering Priced

  Relay Therapeutics priced an underwritten public offering of 22,916,667 shares of common stock at $12.00 per share. The underwriters fully exercised their 30-day option to purchase an additional 3,437,500 shares, bringing the total to 26,354,167 shares.

• Significant Capital Raise

  The company expects to receive approximately $296.8 million in net proceeds from the offering, after deducting underwriting discounts and estimated offering expenses.

• Funding for Pipeline Advancement

  This capital infusion is critical for advancing the company's drug development programs, particularly following recent positive clinical data and a Breakthrough Therapy designation for its lead candidate, zovegalisib.

• Dilution at a Discount

  The offering is dilutive to existing shareholders and priced at $12.00 per share, representing a discount to the current market price of $13.72.

auto_awesomeAnalysis · RLAY · Life Sciences

Relay Therapeutics has finalized a significant public offering, raising approximately $296.8 million in net proceeds. This capital raise, priced at a discount to the current market, is crucial for funding the company's operations and advancing its drug pipeline, especially following recent positive clinical data and a Breakthrough Therapy designation for zovegalisib. While dilutive, it strengthens the company's financial position and extends its cash runway.